官方服务：
资源简介：
CaSR modulator in neuroblastoma model [human]
应用场景：
创建时间：
2016-03-30
相关数据集
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma [microarray]. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma [microarray]
Drugs that modify the epigenome are powerful tools for treating cancer, but these drugs often have pleiotropic effects, and identifying patients who will benefit from them remains a major clinical cha
NIAID Data Ecosystem80
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been la
NIAID Data Ecosystem50
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Histone deacetylase 6 (HDAC6) has been targeted in clinical studies for anticancer effects due to its role in oncogenic transformation and metastasis. Through a second-generation structure–activity re
NIAID Data Ecosystem40
Targeting transcription-replication conflicts is an effective therapeutic principle for MYCN-driven neuroblastoma [ChIPseq_IMR5_RNAseqH1]
Targeting the function of MYC proteins for therapy is a major challenge in tumor biology. MYC proteins are transcription factors that can globally release RNA polymerase II (RNAPII) from core promoter
NIAID Data Ecosystem50
TABLE 2 from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Treatment regimens administered to Kelly xenografts
NIAID Data Ecosystem50
